Story

BMW Recalls Over 29,000 US Vehicles on Fire Risk from Starter Relay

ENTHMSVIIDZHZH-TWJAKOHI
Jul 14, 20261 min read
BMW Recalls Over 29,000 US Vehicles on Fire Risk from Starter Relay

Summary

The German automaker is recalling 29,119 vehicles in the United States due to a faulty engine starter relay that could corrode and short circuit, increasing the risk of a fire, according to a federal safety filing.

Text size
Background

BMW is recalling 29,119 vehicles in the U.S. following a notice from the National Highway Traffic Safety Administration (NHTSA) about a potential fire risk. The issue stems from an engine starter relay that may corrode, leading to overheating and a possible short circuit.

Recall Details

The U.S. auto safety regulator stated on Tuesday that the corrosion of the engine starter relay presents a significant safety hazard. An overheated or short-circuited relay increases the likelihood of a vehicle fire, both while driving and when parked.

The recall affects several models, including:

  • 530e xDrive
  • 740Le xDrive
  • Other unspecified iPerformance models
Sample IUX Markets – In-articleAd

Remedy and Next Steps

According to the NHTSA filing, BMW will address the defect by having its dealers replace the engine starter on all affected vehicles. This service will be performed free of charge to vehicle owners.

BMW is expected to notify owners of the affected vehicles in the coming weeks with instructions on how to schedule the repair. Vehicle recalls are a standard procedure for addressing potential safety defects and are closely monitored by federal regulators to ensure compliance and consumer safety.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST